Exhibit 99.1 Corporate Updates Awaiting FDA action on NDA for YUTREPIA (treprostinil) inhalation powder On March 28, 2025, the U.S. Food and Drug Administration (FDA) accepted Liquidia's New Drug Application (NDA) resubmission for YUTREPIA (treprostinil) inhalation powder to treat PAH and PH-ILD as a complete Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 202 ...